Khaled Alabdulkareem

Khaled Alabdulkareem

Auto-generated profile, based on publicly available information

Khaled Alabdulkareem

Department of Primary Health Care, Ministry of Health, Riyadh 11176, Saudi Arabia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2021 in Healthcare
Verified
Journal Article
Open access
PDF file
MDManal Matar H Al Daajani
Manal Matar H Al Daajani
DADina Mohammed Al-Habib
Dina Mohammed Al-Habib
MIMona Ibrahim
Mona Ibrahim
NSNora Al Shewear
Nora Al Shewear
YFYahya Mohammad Fagihi
Yahya Mohammad Fagihi
KAKhaled Ibrahim Alabdulkareem
Khaled Ibrahim Alabdulkareem
The Saudi Ministry of Health (MOH) established a National School-Based Screening Program (NSBSP) for health screening of schoolchildren. Students from specific grades were systematically screened for several health problems, including obesity, visual and auditory problems, dental cavities, scoliosis, and attention-deficit/hyperactivity disorder (ADHD). This cross-sectional study aimed to determine the prevalence of these health problems among primary school students based on secondary data obtained from the NSBSP. We included 444,259 screened school children from the first and fourth grades of 50% of the selected schools (both private and public) across the Kingdom of Saudi Arabia (KSA) during the academic year 2018–2019. Among them, the most prevalent health problems identified were dental cavities (38.7%), eye refractory errors (10.9%), and overweight and obesity (10.5%); the less prevalent problems included ADHD (2.81%), auditory problems (0.6%), and scoliosis (0.48%). A greater prevalence of most health problems was observed in girls more than boys. The NSBSP successfully aided the detection of health conditions with high and low prevalence among primary school students in the KSA, and thus, the identification of health problems of specific concern. Implementation of effective school health services for the prevention, early detection, diagnosis, and treatment of these health problems are imperative.

16 September 2021 in Healthcare
Verified
Journal Article
Open access
PDF file
KAKhalid Al-Mansour
Khalid Al-Mansour
SASaad Alyahya
Saad Alyahya
FAFouad Abogazalah
Fouad Abogazalah
KAKhaled Alabdulkareem
Khaled Alabdulkareem
Vaccine refusal or hesitancy is one of the significant issues that can have an adverse impact on people’s health and their countries’ economy. Additionally, vaccine acceptance or refusal could have a decisive role in controlling the COVID-19 pandemic. This study aims to investigate the factors affecting COVID-19 vaccine refusal and hesitancy among the general population in Saudi Arabia. The method is a cross-sectional survey using an online questionnaire, and data were collected from 1935 participants between 18 February 2021 and 1 April 2021. Out of 1935 participants aged ≥18 years and residing in Saudi Arabia, 46.9% reported their intention to receive the COVID-19 vaccine, 22.4% had received the vaccine, 9.5% did not intend to receive the vaccine, and 21.2% had not made their decision. In the multinomial logistic regression models, vaccine refusal was associated with age (OR: 0.961), nationality (OR: 0.182), monthly income of more than SAR 18,000 (OR: 2.325), chronic diseases (OR: 0.521), knowledge about the vaccine (OR: 0.937), and concerns about the vaccine (OR: 1.5). The hesitancy was associated with age (OR: 0.977), nationality (OR: 0.231), monthly income between SAR 6000 to 12,000 (OR: 0.607), chronic diseases (OR: 0.640), knowledge about the vaccine (OR: 0.907), and concerns about the vaccine (OR: 1.3). The main concerns about the vaccine were “COVID-19 vaccines are not tested enough on people”, “drug companies are interested in COVID-19 vaccine sales only”, and “COVID-19 vaccines have serious adverse effects”. Awareness programs and vaccination campaigns should consider people’s concerns and correct their misinformation.

10 October 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
Mariam Mohammed Ali AlEissaMariam Mohammed Ali AlEissa
Mariam Mohammed Ali AlEissa
AAAhdab Alsaieedi
Ahdab Alsaieedi
RAReema Alduaiji
Reema Alduaiji
FAFahad Almsned
Fahad Almsned
YAYousif AlDossary
Yousif AlDossary
Abdullah M. AsiriAbdullah M. Asiri
Abdullah M. Asiri
Background: In the Kingdom of Saudi Arabia, various COVID-19 vaccines were administered during the pandemic. However, region-specific real-word comparative data on their immunogenicity remain limited. This study aimed to assess the serological responses to Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273), and AstraZeneca (ChAdOx1 nCoV-19) vaccines in a diverse population living in KSA. Methods: This observational study included 236 adults recruited from vaccination sites in Riyadh. Participants provided serum samples at predefined intervals: before the first dose, after the first dose, after the second dose, and post-vaccination infection (if applicable). IgG and neutralising antibodies were quantified using ELISA assays. Demographic and vaccination data, and their associations with antibody responses, were evaluated. Results: At baseline, 75.4% of participants were positive for SARS-CoV-2 IgG, suggesting high prior exposure. Marked incremental increases in IgG levels were observed after each vaccine dose. Both Moderna and Pfizer elicited stronger responses, with Pfizer inducing the strongest early response and Moderna achieving the highest overall titres. Among IgG-positive individuals, neutralising antibodies were detected in 98.1%. There were no statistically significant differences by age or gender, although males tended to show higher mean titres. Heterologous vaccine schedules induced comparable or enhanced immunogenicity relative to homologous schedules, supporting their use in flexible immunisation strategies. Conclusions: All COVID-19 vaccines administered in Saudi Arabia elicited robust antibody responses, particularly the mRNA-based vaccines. Our findings support their continued use and justify varied vaccination approaches, including mix-and-match booster strategies, to enhance community immunity.

1 January 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
AMAbdulrhman Mohana
Abdulrhman Mohana
TSTarek Sulaiman
Tarek Sulaiman
NMNagla Mahmoud
Nagla Mahmoud
MHMustafa Hassanein
Mustafa Hassanein
AAAmel Alfaifi
Amel Alfaifi
FAFahad Alrabiah
Fahad Alrabiah
Global healthcare is challenged following the COVID-19 pandemic, since late 2019. Multiple approaches have been performed to relieve the pressure and support existing healthcare. The Saudi Arabian Ministry of Health (MOH) launched an initiative to support the National Healthcare System. Since the 5th of June 2020, 238 outpatient fever clinics were established nationwide. This study aimed to assess the safety outcome and reported adverse events from hydroxychloroquine use among suspected COVID-19 patients. A cross-sectional study included 2,733 patients subjected to MOH treatment protocol (hydroxychloroquine) and followed-up within 3-7 days after initiation. Data was collected through an electronic link and cross-checked with the national database (Health Electronic Surveillance Network, HESN) and reports from the MOH Morbidity and Mortality (M&M) Committee. 240 patients (8.8%) discontinued treatment because of side effects (4.1%) and for non-clinical reasons in the remaining (4.7%). Adverse effects were reported among (6.7%) of all studied participants, including mainly cardiovascular (2.5%, 0.15% with QTc prolongation), and gastrointestinal (2.4%). No Intensive Care Unit admission or death were reported among these patients. Our results show that hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects.

13 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
TSTarek Sulaiman
Tarek Sulaiman
AMAbdulrhman Mohana
Abdulrhman Mohana
LALaila Alawdah
Laila Alawdah
NMNagla Mahmoud
Nagla Mahmoud
MHMustafa Hassanein
Mustafa Hassanein
FAFahad Alrabiah
Fahad Alrabiah
BACKGROUND: Currently, there is no proven effective therapy nor vaccine for the treatment of SARS-CoV-2. Evidence regarding the potential benefit of early administration of hydroxychloroquine (HCQ) therapy in symptomatic patients with Coronavirus Disease (COVID-19) is not clear. METHODS: This observational prospective cohort study took place in 238 ambulatory fever clinics in Saudi Arabia, which followed the Ministry of Health (MOH) COVID-19 treatment guideline. This guideline included multiple treatment options for COVID-19 based on the best available evidence at the time, among which was Hydroxychloroquine (HCQ). Patients with confirmed COVD-19 (by reverse transcriptase polymerase chain reaction (PCR) test) who presented to these clinics with mild to moderate symptoms during the period from 5-26 June 2020 were included in this study. Our study looked at those who received HCQ-based therapy along with supportive care (SC) and compared them to patients who received SC alone. The primary outcome was hospital admission within 28-days of presentation. The secondary outcome was a composite of intensive care admission (ICU) and/or mortality during the follow-up period. Outcome data were assessed through a follow-up telephonic questionnaire at day 28 and were further verified with national hospitalisation and mortality registries. Multiple logistic regression model was used to control for prespecified confounders. RESULTS: Of the 7,892 symptomatic PCR-confirmed COVID-19 patients who visited the ambulatory fever clinics during the study period, 5,541 had verified clinical outcomes at day 28 (1,817 patients in the HCQ group vs 3,724 in the SC group). At baseline, patients who received HCQ therapy were more likely to be males who did not have hypertension or chronic lung disease compared to the SC group. No major differences were noted regarding other comorbid conditions. All patients were presenting with active complaints; however, the HCQ groups had higher rates of symptoms compared to the SC group (fever: 84% vs 66.3, headache: 49.8 vs 37.4, cough: 44.5 vs 35.6, respectively). Early HCQ-based therapy was associated with a lower hospital admission within 28-days compared to SC alone (9.4% compared to 16.6%, RRR 43%, p-value <0.001). The composite outcome of ICU admission and/or mortality at 28-days was also lower in the HCQ group compared to the SC (1.2% compared to 2.6%, RRR 54%, p-value 0.001). Adjusting for age, gender, and major comorbid conditions, a multivariate logistic regression model showed a decrease in the odds of hospitalisation in patients who received HCQ compared to SC alone (adjusted OR 0.57 [95% CI 0.47-0.69], p-value <0.001 ). The composite outcome of ICU admission and/or mortality was also lower for the HCQ group compared to the SC group controlling for potential confounders (adjusted OR 0.55 [95% CI 0.34-0.91], p-value 0.019). CONCLUSION: Early intervention with HCQ-based therapy in patients with mild to moderate symptoms at presentation is associated with lower adverse clinical outcomes among COVID-19 patients, including hospital admissions, ICU admission, and/or death.

23 August 2021 in Saudi Journal of Emergency Medicine
Verified
Journal Article
Closed access
YOUSEF M ALSOFAYANYOUSEF M ALSOFAYAN
YOUSEF M ALSOFAYAN
FAFahad A Alamri
Fahad A Alamri
FAFaten AlRadini
Faten AlRadini
NRNashwa M. Radwan
Nashwa M. Radwan
AKAnas Khan
Anas Khan
KAKhaled I. Alabdulkareem
Khaled I. Alabdulkareem
Background: Hajj is an annual religious ritual that takes place for a specific period in Makkah city. Every year, the Kingdom of Saudi Arabia hosts more than two million pilgrims from more than 160 countries around the world for Hajj. It is crucial to minimize illnesses among pilgrims. This study aimed to assess the impact of preventive measures on acute illnesses among pilgrims. Methods: A retrospective cross-sectional study was conducted during the Hajj season from August to September 2019. A random sample was extracted from electronic evaluation forms filled by professional health care workers at two airports in Saudi Arabia including pilgrims before their departure and after the end of hajj season. Results: The study included 2,479 pilgrims. The most frequently associated comorbidity was Diabetes Mellitus in 49.54%. Upper respiratory tract infection was found in 39.17% and was the most common illness reported. Comorbidities had a crude odds ratio (OR) of 2.67 with a p-value of 0.000 and an adjusted OR of 2.80 with p-value of 0.000. The pre-Hajj examination had an OR of 0.37 with a p-value 0.000 that remained significant even after adjusting age and gender. Hajj health education had a crude OR of 0.17 with a significant p-value of 0.000 and adjusted OR 0.39 with p-value 0.003. Conclusion: Based on the current observation, strict compliance with standard pre-Hajj clinical examination, health education, and the use of umbrella during Hajj seasons is recommended to reduce the impact of acute illness among pilgrims.